304 related articles for article (PubMed ID: 15198117)
1. NSAIDs: gastroprotection or selective COX-2 inhibitor?
Dickman A; Ellershaw J
Palliat Med; 2004 May; 18(4):275-86. PubMed ID: 15198117
[TBL] [Abstract][Full Text] [Related]
2. A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling.
Brown TJ; Hooper L; Elliott RA; Payne K; Webb R; Roberts C; Rostom A; Symmons D
Health Technol Assess; 2006 Oct; 10(38):iii-iv, xi-xiii, 1-183. PubMed ID: 17018227
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of cyclooxygenase-2-specific inhibitors.
Cannon GW; Breedveld FC
Am J Med; 2001 Feb; 110 Suppl 3A():6S-12S. PubMed ID: 11173044
[TBL] [Abstract][Full Text] [Related]
4. Review article: NSAIDs, gastroprotection and cyclo-oxygenase-II-selective inhibitors.
Micklewright R; Lane S; Linley W; McQuade C; Thompson F; Maskrey N
Aliment Pharmacol Ther; 2003 Feb; 17(3):321-32. PubMed ID: 12562444
[TBL] [Abstract][Full Text] [Related]
5. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review.
Hooper L; Brown TJ; Elliott R; Payne K; Roberts C; Symmons D
BMJ; 2004 Oct; 329(7472):948. PubMed ID: 15475342
[TBL] [Abstract][Full Text] [Related]
6. [The coxibs, third generation anti-inflammatories].
Sternon J
Rev Med Brux; 2001 Apr; 22(2):100-5. PubMed ID: 11388024
[TBL] [Abstract][Full Text] [Related]
7. Gastrointestinal toxic side effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2-specific inhibitors.
Buttgereit F; Burmester GR; Simon LS
Am J Med; 2001 Feb; 110 Suppl 3A():13S-9S. PubMed ID: 11173045
[TBL] [Abstract][Full Text] [Related]
8. The new NSAIDs: cox-2 inhibitors.
Capriotti T
Medsurg Nurs; 2000 Dec; 9(6):313-7. PubMed ID: 11904867
[No Abstract] [Full Text] [Related]
9. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.
Hochberg MC
Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S15-22. PubMed ID: 11695246
[TBL] [Abstract][Full Text] [Related]
10. A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database.
Zhao SZ; Reynolds MW; Lejkowith J; Whelton A; Arellano FM
Clin Ther; 2001 Sep; 23(9):1478-91. PubMed ID: 11589261
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of nonsteroidal anti-inflammatory drug-induced gastrointestinal injury and repair: a window of opportunity for cyclooxygenase-inhibiting nitric oxide donors.
Perini R; Fiorucci S; Wallace JL
Can J Gastroenterol; 2004 Apr; 18(4):229-36. PubMed ID: 15054499
[TBL] [Abstract][Full Text] [Related]
12. COX-2-specific inhibition: implications for clinical practice.
Pascucci RA
J Am Osteopath Assoc; 1999 Nov; 99(11 Suppl):S18-22. PubMed ID: 10643177
[TBL] [Abstract][Full Text] [Related]
13. The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis.
Spiegel BM; Targownik L; Dulai GS; Gralnek IM
Ann Intern Med; 2003 May; 138(10):795-806. PubMed ID: 12755551
[TBL] [Abstract][Full Text] [Related]
14. COX-2-Selective NSAIDs: new and improved?
Lichtenstein DR; Wolfe MM
JAMA; 2000 Sep; 284(10):1297-9. PubMed ID: 10980759
[No Abstract] [Full Text] [Related]
15. Arthritis treatment in Hong Kong--cost analysis of celecoxib versus conventional NSAIDS, with or without gastroprotective agents.
You JH; Lee KK; Chan TY; Lau WH; Chan FK
Aliment Pharmacol Ther; 2002 Dec; 16(12):2089-96. PubMed ID: 12452942
[TBL] [Abstract][Full Text] [Related]
16. The coxibs, selective inhibitors of cyclooxygenase-2.
FitzGerald GA; Patrono C
N Engl J Med; 2001 Aug; 345(6):433-42. PubMed ID: 11496855
[No Abstract] [Full Text] [Related]
17. Underutilization of preventive strategies in patients receiving NSAIDs.
Sturkenboom MC; Burke TA; Dieleman JP; Tangelder MJ; Lee F; Goldstein JL
Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii23-31. PubMed ID: 14585915
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789
[TBL] [Abstract][Full Text] [Related]
19. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.
Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
Am J Manag Care; 2002 Oct; 8(15 Suppl):S414-27. PubMed ID: 12416791
[TBL] [Abstract][Full Text] [Related]
20. [COX-2 inhibitor non-steroidal anti-inflammatory drugs, myth or reality?].
Peretz A
Rev Med Brux; 2001 Sep; 22(4):A377-80. PubMed ID: 11680204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
